ImmunityBio, Inc. IBRX Total debt
Total debt at other companies
Other financials
Where this comes from
Calculated from ImmunityBio, Inc.’s reported figures.
$404.3Mlong term debt+$53.0Kcurrent portion long term debt+$213.0Kfinance lease liabilities=$445.39M
Plus components not separately reported this period.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s total debt?
- ImmunityBio, Inc. (IBRX) reported total debt of $445.39M in Q1 2026.
- How has ImmunityBio, Inc.'s total debt changed year-over-year?
- ImmunityBio, Inc.'s total debt increased by 32.2% year-over-year, from $336.84M to $445.39M.
- What is the long-term trend for ImmunityBio, Inc.'s total debt?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s total debt has grown at a 88.7% compound annual growth rate (CAGR), from $15.31M to $365.93M.
- What does total debt mean?
- The total amount of money a company owes to lenders, banks, and lessors.
- How do you interpret total debt?
- An increase in total debt suggests higher financial leverage and increased interest expense, which may heighten bankruptcy risk for clinical-stage firms, while a decrease indicates deleveraging or improved capital structure stability.
- How does total debt compare across companies?
- In the biotechnology sector, total debt levels vary significantly based on the company's clinical stage and cash burn rate; early-stage firms often maintain lower debt to avoid interest burdens, while commercial-stage peers may carry higher debt to fund manufacturing and distribution.